Leveraging the established EZ-fill® market-leading
technology, process, and product optimization to improve quality,
reduce total cost of ownership, and shorten lead times
Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug
containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries, and
Gerresheimer AG, a leading global provider of healthcare &
beauty and drug delivery systems for pharma, biotech and cosmetics,
announced today at CPhl Worldwide the official launch of a new and
innovative ready-to-use (RTU) vial platform, EZ-fill Smart™, a
solution designed to improve drug packaging quality, reduce total
cost of ownership (TCO), and shorten lead times for customers. The
new EZ-fill Smart™ is an evolution of Stevanato Group’s
groundbreaking EZ-fill® platform, and it brings new advancements
that can create significant enhancements to customer product
offerings amid growing demand for RTU vials.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221101006001/en/
Stevanato Group and Gerresheimer AG
present EZ-fill Smart™, a new and innovative Ready-To-Use vial
platform (Photo: Business Wire)
The companies have implemented process and product changes that
can offer substantial improvements for customers. The EZ-fill
Smart™ platform leverages increased automation throughout the
manufacturing process to increase productivity and reduce human
errors. The optimized platform features no glass-to-glass and no
glass-to-metal contact, which improves quality and integrity of the
vials throughout the product life cycle. The companies have
redesigned the secondary packaging, which can yield a significant
reduction of particle risks during customers’ operations,
delivering improved quality.
The new EZ-fill Smart™ now offers the market a sterilization
method that is more environmentally friendly compared to
traditional Ethylene Oxide (EtO) sterilization, and that is an
alternative sterilization method that can result in improved
safety. Intended to be suited for primary packaging solutions in
use with highly sensitive drugs, it also incorporates guidelines
given by regulatory bodies supporting the current direction to
replace EtO sterilization. Together, Stevanato Group and
Gerresheimer AG have obtained positive results to date and are in
the validation process with this sustainable sterilization
method.
EZ-fill Smart™ is intended to improve sustainability in multiple
areas, increasing the packaging efficiency, implementing a new
eco-friendly sterilization method, and using biopolymers and
recycled plastic.
Developed in close cooperation with major machine vendors,
EZ-fill Smart™ can provide a proven seamless integration with
standard fill & finish operations. The platform also
accommodates both small and large batch production. The companies
have implemented advancements that can help ensure the
processability on filling lines with the primary aim to facilitate
the complete automation of the in-feeding process. Along with the
Nest & Tub configuration, EZ-fill Smart™ will also be available
in tray configuration to support and accelerate the conversion from
bulk to RTU vials that is already underway in the market. Customers
choosing this option can benefit from the improvements gained with
the newly designed Nest & Tub configuration.
EZ-fill Smart™ with Nest & Tub configuration, including
process and product optimization, is expected to be available for
the commercial phase during the first half of 2024. By mid-2023 the
new solution is expected to be available to customers for initial
validation. EZ-fill Smart™ with tray configuration for high volume
is expected to be available on the market during the first half of
2024.
“Our EZ-fill® technology is a
well-established standard in the industrial process for RTU primary
containment solutions, and the new and innovative EZ-fill Smart™
platform responds to increasing demand from customers for RTU
products,” said Mauro Stocchi, Chief Business Officer at Stevanato
Group. “We believe EZ-fill Smart™ will help pharma companies, CMOs,
and CDMOs easily adopt the market-leading technology by optimizing
quality, costs, and machinability while keeping our environmental
impact in mind.”
“As an innovative and leading solution
provider for the pharma and biotech industry, Gerresheimer responds
to customer demand with a best-in-class solution. We are convinced
that the new EZ-fill Smart™ platform is the next industry standard
for RTU vials and in the future also for cartridges,” said Lukas
Burkhardt, Member of the Executive Board of Gerresheimer AG. “The
new platform will enable customers to optimize their processes,
improve their quality and their CO2 footprint. In addition, our
customers can benefit from a significant reduction in the total
cost of ownership.”
EZ-fill Smart™ will be officially presented at CPhI Worldwide on
November 1-3, 2022, in Frankfurt at Stevanato Group (booth 30F30 in
hall 3.0) and Gerresheimer AG (booth 30 B21 in hall 3.0).
For more information, visit www.stevanatogroup.com or
www.gerresheimer.com.
Forward-Looking Statements
This press release may include forward-looking statements. The
words “growing,” “improves,” “will,” “expected,” “aim,”
“increasing,” and similar expressions (or their negative) identify
certain of these forward-looking statements. These forward-looking
statements are statements regarding the Companies’ intentions,
beliefs or current expectations concerning the collaboration. The
forward-looking statements in this press release are based on
numerous assumptions regarding the Companies’ present and future
business strategies and the environment in which each Company will
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements of the Companies to be materially
different from those expressed or implied by such forward-looking
statements. Many of these risks and uncertainties relate to factors
that are beyond the Companies' ability to control or estimate
precisely, such as future market conditions, currency fluctuations,
the behavior of other market participants, the actions of
regulators and other factors such as the Companies' ability to
continue to obtain financing to meet its liquidity needs, changes
in the political, social and regulatory framework in which the
Company operates or in economic or technological trends or
conditions. Readers should therefore not place undue reliance on
these statements, particularly not in connection with any contract
or investment decision. Except as required by law, none of the
companies assumes no obligation to update any such forward-looking
statements.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of
drug containment, drug delivery and diagnostic solutions to the
pharmaceutical, biotechnology and life sciences industries. The
Group delivers an integrated, end-to-end portfolio of products,
processes and services that address customer needs across the
entire drug life cycle at each of the development, clinical and
commercial stages. Stevanato Group’s core capabilities in
scientific research and development, its commitment to technical
innovation and its engineering excellence are central to its
ability to offer value added solutions to clients. To learn more,
visit: www.stevanatogroup.com.
About Gerresheimer AG
Gerresheimer is the global partner for pharmaceutics, biotech,
healthcare, and cosmetics with a very broad product range for
pharmaceutical and cosmetic packaging solutions and drug delivery
systems. The company is an innovative solution provider from
concept to delivery of the end product. Gerresheimer achieves its
ambitious goals through a high level of innovative strength,
industrial competence and concentration on quality and customer
focus. In developing innovative and sustainable solutions,
Gerresheimer relies on a comprehensive international network with
numerous innovation and production centers in Europe, America and
Asia. Gerresheimer produces close to its customers worldwide with
around 11,000 employees and generated annual revenues in 2021 of
around EUR 1.5b. With its products and solutions, Gerresheimer
plays an essential role in people's health and well-being. For more
information: www.gerresheimer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101006001/en/
Media contact Stevanato Group media@stevanatogroup.com
Cassie Gonzalez: stevanatoUS@teamlewis.com
Investor Relations Stevanato Group Lisa Miles:
lisa.miles@stevanatogroup.com
Contact Press Gerresheimer AG Ueli Utzinger Group Senior
Director Marketing & Communication T +49 211 6181-250
ueli.utzinger@gerresheimer.com
Contact Investor Relations Gerresheimer AG Carolin Nadilo
Corporate Senior Director Investor Relations T +49 211 6181-220
carolin.nadilo@gerresheimer.com
Stevanato (NYSE:STVN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stevanato (NYSE:STVN)
Historical Stock Chart
From Apr 2023 to Apr 2024